Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?
DAVID MOLITERNO, University of Kentucky, Lexington
REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.
[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070325_david_moliterno.mp3]An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.
